Digitalis: A dangerous drug in atrial fibrillation? An analysis of the SPORTIF III and V data

Heart

Volumn 94, Issue 2, 2008, Pages 191-196

  Gjesdal, K ^a   Feyzi, J ^b   Olsson, S B ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DIGITALIS; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN; ANTICOAGULANT AGENT; AZETIDINE DERIVATIVE; BENZYLAMINE DERIVATIVE; CARDIOTONIC AGENT; DIGITALIS GLYCOSIDE; PLANT MEDICINAL PRODUCT;

AGED; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EMBOLISM PREVENTION; FEMALE; HAZARD RATIO; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SURVIVAL; THROMBOEMBOLISM; THROMBOSIS PREVENTION; COMPARATIVE STUDY; DOUBLE BLIND PROCEDURE; KAPLAN MEIER METHOD; MULTICENTER STUDY; PHYTOTHERAPY; STROKE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CARDIOTONIC AGENTS; DIGITALIS; DIGITALIS GLYCOSIDES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; PHYTOTHERAPY; PLANT PREPARATIONS; STROKE; THROMBOEMBOLISM; WARFARIN;

EID: 38749126254     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.2006.108399     Document Type: Article

References (25)

1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur Heart J 2001;22:1852-923.
2. Bayram M, De Luca L, Massie MB, et al. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes. Am J Cardiol 2005;96:47-58G.
3. Anonymous. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group. N Engl J Med 1997;336:525-33.
4. Olsson SB, The Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003;362:1691-8.
5. Albers GW, Diener HC, Frison L, et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005;293:690-8.
6. The AFFIRM Investigators. Relationships between sinus rhythm, treatment and survival in the atrial fibrillation follow-up investigation of rhythm management (AFFIRM) study. Circulation 2004;109:1509-13.
7. Byington R, Goldstein S. Association of digitalis therapy with mortality in survivors of acute myocardial infarction: observations in the Beta-Blocker Heart Attack Trial. J Am Coll Cardiol 1985;6:976-82.
8. Ordog GJ, Benaron S, Bhasin V, et al. Serum digoxin levels and mortality in 5,100 patients. Ann Emerg Med 1987;16:32-9.
9. Kernan WN, Castellsague J, Perlman GD, et al. Incidence of hospitalization for digitalis toxicity among elderly Americans. Am J Med 1994;96:426-31.
10. Thummel KE, Shen DD. Design and optimization of dosage regime. Pharmacologic data. In: Hardman JG, Kimbird LE, eds. Goodman and Gilman's the pharmacological basis of therapeutics. New York, USA: McGraw Hill, 2001.
11. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002;347:1403-11.
12. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003;289:871-8.
13. Domanski M, Fleg J, Bristow M, et al. The effect of gender on outcome in digitalis-treated heart failure patients. J Card Fail 2005;11:83-6.
14. Antman EM, Wenger TL, Butler VP Jr, et al. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation 1990;81:1744-52.
15. Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part I. Prog Cardiovasc Dis 1984;26:413-58.
16. Smith TW, Antman EM, Friedman PL, et al. Digitalis glycosides: mechanisms and manifestations of toxicity. Part II. Prog Cardiovasc Dis 1984;26:495-540.
17. Lees AD, Wilson J, Orchard CH, et al. Ouabain enhances basal and stimulus-induced cytoplasmic calcium concentrations in platelets. Thromb Haemost 1989;62:1000-5.
18. Pettersen E, Hagberg IA, Lyberg T, et al. Do cardiac glycosides affect platelet function? A flow cytometric study in healthy volunteers. Eur J Clin Pharmacol 2002;58:181-6.
19. Kamath S, Blann AD, Lip GY. Platelets and atrial fibrillation. Eur Heart J 2001;22:2233-42.
20. Minamino T, Kitakaze M, Asanuma H, et al. Plasma adenosine levels and platelet activation in patients with atrial fibrillation. Am J Cardiol 1999;83:194-8.
21. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
22. Pongratz G, Brandt-Pohlmann M, Henneke KH, et al. Platelet activation in embolic and preembolic status of patients with nonrheumatic atrial fibrillation. Chest 1997;111:929-33.
23. Minamino T, Kitakaze M, Sanada S, et al. Increased expression of P-selectin on platelets is a risk factor for silent cerebral infarction in patients with atrial fibrillation: role of nitric oxide. Circulation 1998;98:1721-7.
24. Chirinos JA, Castrellon A, Zambrano JP, et al. Digoxin use is associated with increased platelet and endothelial cell activation in patients with nonvalvular atrial fibrillation. Heart Rhythm 2005;2:525-9.
25. Kannel WB, Abbott RD, Savage DD, et al. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J 1983;106:389-96.